

# WEST

## Collections

### Definition, Editing, Browsing

Name: Undefined

Contents:

wo9508576  
de4332256  
wo9639437  
wo9722698  
wo9726009  
wo9732019  
wo9745543

Comment:

Database:

US Patents Full-Text Database  
US Patents Pre-Grant Publication Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

Save

Save As

Help

Reset

Quit

Print

Search

Get Images

Classification Info

Main Menu

Collection Directory

Logout

**PCT**WELTORGANISATION FÜR GEISTIGES EIGENTUM  
Internationales BüroINTERNATIONALE ANMELDUNG VERÖFFENTLICHT NACH DEM VERTRAG ÜBER DIE  
INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT)

<b>(51) Internationale Patentklassifikation <sup>6</sup> :</b> <b>C07K 16/28, A61K 39/395, G01N 33/577, C12P 21/08</b>		<b>A1</b>	<b>(11) Internationale Veröffentlichungsnummer: WO 95/08576</b>
			<b>(43) Internationales Veröffentlichungsdatum:</b> 30. März 1995 (30.03.95)
<b>(21) Internationales Aktenzeichen:</b> PCT/EP94/03175		<b>(81) Bestimmungsstaaten:</b> JP, US, europäisches Patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
<b>(22) Internationales Anmeldedatum:</b> 22. September 1994 (22.09.94)			
<b>(30) Prioritätsdaten:</b> P 43 32 256.5 22. September 1993 (22.09.93) DE		<b>Veröffentlicht</b> <i>Mit internationalem Recherchenbericht. Vor Ablauf der für Änderungen der Ansprüche zugelassenen Frist. Veröffentlichung wird wiederholt falls Änderungen eintreffen.</i>	
<b>(71)(72) Anmelder und Erfinder:</b> LIPP, Martin [DE/DE]; Trappentreustraße 23, D-80339 München (DE).			
<b>(72) Erfinder; und</b>			
<b>(75) Erfinder/Anmelder (nur für US):</b> FÖRSTER, Reinhold [DE/DE]; Stüftbogen 57, D-81357 München (DE). EM-RICH, Thomas [DE/DE]; Blombergstrasse 9, D-82393 Iffeldorf (DE). WOLF, Ingrid [DE/DE]; Thalkirchnerstrasse 143, D-81371 München (DE). KREMMER, Elisabeth [DE/DE]; Untere Hauptstrasse 28, D-85354 Freising (DE).			
<b>(74) Anwalt:</b> MÜLLER-BORÉ & PARTNER; Isartorplatz 6, D-80331 München (DE).			
<b>(54) Title:</b> MONOCLONAL ANTIBODIES AGAINST LEUKOCYTE-SPECIFIC G-PROTEIN-COUPLED RECEPTORS			
<b>(54) Bezeichnung:</b> MONOKLONALE ANTIKÖRPER GEGEN LEUKOZYTEN-SPEZIFISCHE G-PROTEIN-GEKOPPELTE REZEPTOREN			
<b>(57) Abstract</b> <p>Monoclonal antibodies against leukocyte-specific G-protein-coupled receptors (L-GCR) are disclosed. These antibodies may be produced by the following steps: (a) introduction of a L-GCR coding nucleic acid into cells and expression of L-GCR; (b) immunisation of animals with L-GCR-expressing cells (a); and (c) fusion of spleen cells from the immunised animals (b) with myeloma cells and production of monoclonal L-GCR antibody-producing hybridoma cells. Also disclosed is a process for producing such antibodies, their use and kits containing the same, as well as a process for producing monoclonal GCR antibodies.</p>			
<b>(57) Zusammenfassung</b> <p>Die Erfindung betrifft monoklonale Antikörper gegen Leukozyten-spezifische G-Protein-gekoppelte Rezeptoren (L-GCR). Diese Antikörper sind durch folgende Verfahrensschritte erhältlich: (a) Einführung einer L-GCR-codierenden Nukleinsäure in Zellen und Expression von L-GCR, (b) Immunisierung eines Tieres mit L-GCR-exprimierenden Zellen von (a), und (c) Fusion von Milzzellen des immunisierten Tieres von (b) mit Myelomzellen und Erhalt von monoklonale L-GCR-Antikörper-produzierenden Hybridomzellen. Ferner betrifft die Erfindung Verfahren zur Herstellung solcher Antikörper, ihre Verwendung und sie enthaltende Kits. Desweiteren betrifft die Erfindung Verfahren zur Herstellung monoklonaler GCR-Antikörper.</p>			



19 BUNDESREPUBLIK  
DEUTSCHLAND



DEUTSCHES  
PATENTAMT

12 Patentschrift  
10 DE 43 32 256 C 1

51 Int. Cl.<sup>8</sup>:  
C 12 N 5/16  
A 61 K 39/395  
G 01 N 33/577  
// C12N 15/85,15/81,  
5/18

21 Aktenzeichen: P 43 32 256.5-41  
22 Anmeldetag: 22. 9. 93  
43 Offenlegungstag: —  
45 Veröffentlichungstag  
der Patenterteilung: 9. 3. 95

DE 43 32 256 C 1

Innerhalb von 3 Monaten nach Veröffentlichung der Erteilung kann Einspruch erhoben werden

73 Patentinhaber:  
Lipp, Martin, Dr. Dr.habil, 80339 München, DE

74 Vertreter:  
Deufel, P., Dipl.-Wirtsch.-Ing.Dr.rer.nat.; Hertel, W.,  
Dipl.-Phys.; Rutetzki, A., Dipl.-Ing.Univ.; Rucker, E.,  
Dipl.-Chem. Univ. Dr.rer.nat.; Huber, B., Dipl.-Biol.  
Dr.rer.nat.; Becker, E., Dr.rer.nat.; Steil, C., Dipl.-Ing.,  
80331 München; Kurig, T., Dipl.-Phys., Pat.-Anwälte,  
83022 Rosenheim

72 Erfinder:  
Lipp, Martin, Dipl.-Biol. Dr., 80339 München, DE;  
Förster, Reinhold, Dr., 81375 München, DE; Emrich,  
Thomas, Dipl.-Chem., 82393 Iffeldorf, DE; Wolf,  
Ingrid, Dipl.-Biol., 81371 München, DE; Kremmer,  
Elisabeth, Dr., 85354 Freising, DE

56 Für die Beurteilung der Patentfähigkeit  
in Betracht gezogene Druckschriften:  
Eur. J. Immunol. 22, S. 2795-2799, 1992;

64 Monoklonale Antikörper gegen Leukozyten-spezifische G-Protein-gekoppelte Rezeptoren

57 Die Erfindung betrifft monoklonale Antikörper gegen  
Leukozyten-spezifische G-Protein-gekoppelte Rezeptoren  
(L-GCR). Diese Antikörper sind durch folgende Verfahrens-  
schritte erhältlich:  
(a) Einführung einer L-GCR-codierenden Nukleinsäure in  
Zellen und Expression von L-GCR,  
(b) Immunisierung eines Tieres mit L-GCR-exprimierenden  
Zellen von (a), und  
(c) Fusion von Milzzellen des immunisierten Tieres von (b)  
mit Myelomzellen und Erhalt von monoklonale L-GCR-Anti-  
körper-produzierenden Hybridomzellen.  
Ferner betrifft die Erfindung Verfahren zur Herstellung  
solcher Antikörper, ihre Verwendung und sie enthaltende  
Kits. Des weiteren betrifft die Erfindung Verfahren zur  
Herstellung monoklonaler GCR-Antikörper.

DE 43 32 256 C 1

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07K 14/705, C12N 15/12</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/39437</b> <b>(43) International Publication Date:</b> 12 December 1996 (12.12.96)
<b>(21) International Application Number:</b> PCT/US95/07173 <b>(22) International Filing Date:</b> 6 June 1995 (06.06.95) <b>(71) Applicant (for all designated States except US):</b> HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850-3338 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LI, Yi [CN/US]; 16125 Howard Landing Drive, Gaithersburg, MD 20878 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). <b>(74) Agents:</b> OLSTEIN, Elliot, M.; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 (US) et al.		<b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, ARIPO patent (KE, MW, SD, SZ, UG), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>With an indication in relation to a deposited microorganism furnished under Rule 13bis separately from the description.</i> <i>Date of receipt by the International Bureau:</i> 1 November 1996 (01.11.96)
<b>(54) Title:</b> HUMAN G-PROTEIN CHEMOKINE RECEPTOR HDGNR10  <b>(57) Abstract</b>  Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.		

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C12N 15/12, C07K 14/705, 16/28, C12N 5/20</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 97/22698</b> <b>(43) International Publication Date:</b> 26 June 1997 (26.06.97)
<b>(21) International Application Number:</b> PCT/US96/20759 <b>(22) International Filing Date:</b> 20 December 1996 (20.12.96)  <b>(30) Priority Data:</b> 08/575,967 20 December 1995 (20.12.95) US 08/661,393 7 June 1996 (07.06.96) US  <b>(71) Applicant:</b> ICOS CORPORATION [US/US]; 22021 20th Avenue S.E., Bothell, WA 98021 (US).  <b>(72) Inventors:</b> GRAY, Patrick, W.; 1600 40th Avenue, Seattle, WA 98122 (US). SCHWEICKART, Vicki, L.; 1421 Orange Place North, Seattle, WA 98109 (US). RAPORT, Carol, J.; 2300 211th Street, S.E., Bothell, WA 98021 (US).  <b>(74) Agent:</b> BORUN, Michael, F.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606-6402 (US).		<b>(81) Designated States:</b> AU, BR, CA, CN, CZ, FI, HU, JP, MX, NO, PL, RU, SK, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> CHEMOKINE RECEPTORS 88-2B[CKR-3] AND 88C AND THEIR ANTIBODIES  <b>(57) Abstract</b>  The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, viral infection, AIDS, and other inflammatory conditions.		

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>A61K 39/395, C12N 5/20, 15/63, 15/12, C07H 21/04</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/26009</b> <b>(43) International Publication Date:</b> 24 July 1997 (24.07.97)
<b>(21) International Application Number:</b> PCT/US97/00758 <b>(22) International Filing Date:</b> 17 January 1997 (17.01.97) <b>(30) Priority Data:</b> 08/587,458 17 January 1996 (17.01.96) US <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 08/587,458 (CIP) Filed on 17 January 1996 (17.01.96) <b>(71) Applicant (for all designated States except US):</b> PROGENICS PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LITWIN, Virginia, M. [US/US]; 205 Canopus Hollow Road, Putnam Valley, NY 10579 (US); ALLAWAY, Graham, P. [GB/US]; 1778 Horton Avenue, Mohegan Lake, NY 10547 (US); MADDON, Paul, J. [US/US]; Apartment 25C, 60 Haven Avenue, New York, NY 10032 (US).	<b>(74) Agent:</b> WHITE, John, P.; Cooper & Dunham L.L.P., 1185 Avenue of the Americas, New York, NY 10036 (US).  <b>(81) Designated States:</b> AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> COMPOUNDS CAPABLE OF INHIBITING HIV-1 INFECTION  <b>(57) Abstract</b>  This invention provides an antibody capable of specifically inhibiting the fusion of an HIV-1 envelope glycoprotein+ cell with an appropriate CD4+ cell without cross reacting with the HIV-1 envelope glycoprotein or CD4 and capable of inhibiting infection by one or more strains of HIV-1. This antibody is then used to identify a molecule which is important for HIV infection. Different uses of the antibody and the molecule are described.		



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12N 15/12, C07K 14/705, 16/28, C12N 5/20	A2	(11) International Publication Number: WO 97/32019
		(43) International Publication Date: 4 September 1997 (04.09.97)

(21) International Application Number: PCT/BE97/00023

(22) International Filing Date: 28 February 1997 (28.02.97)

(30) Priority Data:

96870021.1

(34) Countries  
internati

96870102.9

(34) Countries  
internati(71) Applicant (for a  
SCREEN S.A.  
Brussels (BE).(72) Inventors; and  
(75) Inventors/Applic:  
[FR/FR]; 11, r  
PARMENTIE  
B-1604 Linke  
Avenue Lamé  
Frédéric [BI  
Braine-l'Alleu(74) Agents: VAN MALDEREN, Eric et al.; Office Van Malderen,  
Place Reine-Fabiola 6/1, B-1083 Brussels (BE).(81) Designated States: CA JP US European patent (AT, BE, CH,  
LU, MC, NL, PT,

11 PREPAREDERS

18/9/97

→ For scanning


and to be

o a deposited  
13<sup>th</sup> separatelyau:  
1997 (17.03.97)

(54) Title: C-C CKR-5, CC-CHEMOKINES RECEPTOR, DERIVATIVES THEREOF AND THEIR USES

## (57) Abstract

The present invention is related to new peptides and the nucleic acid molecules encoding said peptides. The present invention concerns also the vector comprising said nucleic acid molecules, cells transformed by said vector, inhibitors directed against said peptides or said nucleic acid molecules, a pharmaceutical composition and a diagnostic and/or dosage device comprising said products, and non human transgenic animals expressing the peptides according to the invention or the nucleic acid molecules encoding said peptides.





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/12, A61K 38/17, C07K 14/715, G01N 33/68, C07K 16/28, A01K 67/027</b>		<b>A2</b>	(11) International Publication Number: <b>WO 97/45543</b> (43) International Publication Date: <b>4 December 1997 (04.12.97)</b>
(21) International Application Number: <b>PCT/US97/09586</b> (22) International Filing Date: <b>28 May 1997 (28.05.97)</b> (30) Priority Data: <b>60/018,508</b> <b>28 May 1996 (28.05.96)</b> <b>US</b> (60) Parent Application or Grant (63) Related by Continuation <b>US</b> <b>60/018,508 (CIP)</b> <b>Filed on</b> <b>28 May 1996 (28.05.96)</b> (71) Applicant (for all designated States except US): <b>THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH [US/US]; Office of Technology Center, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>COMBADIERE, Christophe [-/US]; Rockville, MD (US). FENG, Yu [-/US]; Bethesda, MD (US). BERGER, Edward, A. [-/US]; 5820 Inway Park Circle, Rockville, MD 20852 (US).</b>		<b>ALKHATIB, Ghalib [-/US]; Bethesda, MD (US). MURPHY, Philip, M. [-/US]; Rockville, MD (US). BRODER, Christopher, C. [-/US]; Rockville, MD (US). KENNEDY, Paul, E. [-/US]; 8502 Flower Avenue, Takoma Park, MD 20912 (US).</b>  <b>(74) Agent: HAILE, Lisa, A.; Fish &amp; Richardson, P.C., Suite 1400, 4225 Executive Square, La Jolla, CA 92037 (US).</b>  <b>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: <b>CC CHEMOKINE RECEPTOR 5, ANTIBODIES THERETO, TRANSGENIC ANIMALS</b>			
(57) Abstract  <p>The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.</p>			



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/70, C12N 15/12, 5/10</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/05798</b> <b>(43) International Publication Date:</b> 12 February 1998 (12.02.98)
<b>(21) International Application Number:</b> PCT/US97/13946 <b>(22) International Filing Date:</b> 7 August 1997 (07.08.97)  <b>(30) Priority Data:</b> 08/694,235      8 August 1996 (08.08.96)      US 60/025,230      8 August 1996 (08.08.96)      US  <b>(71) Applicant:</b> THE AARON DIAMOND AIDS RESEARCH CENTER [US/US]; 7th floor, 455 1st Avenue, New York, NY 10016 (US).  <b>(72) Inventors:</b> LANDAU, Nathaniel, R.; Apartment 1514, 200 East 94th Street, New York, NY 10128 (US). KOUPE, Richard, A.; 32 Overlook Road, Ossining, NY 10562 (US). LIU, Rong; Apartment 5M, 400 West 119th Street, New York, NY 10027 (US). PAXTON, William; Apartment #15-N, 4 Washington Square Village, New York, NY 10012 (US).  <b>(74) Agents:</b> DAVIS, Michael, D. et al.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).	<b>(81) Designated States:</b> AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> HIV CORECEPTOR MUTANTS  <b>(57) Abstract</b>  Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains <i>in vivo</i> . It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the $\beta$ -chemokines RANTES, MIP-1 $\alpha$ , and MIP-1 $\beta$ . It has also been found that individuals who are homozygous for a mutation of the CKR-5 receptor are resistant to HIV infection; <i>in vitro</i> infection requires a 1000-fold higher dose of HIV than normal cells. The mutation results in complete suppression of CKR-5 expression.		

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 48/00, 38/19</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/44953</b> <b>(43) International Publication Date:</b> 15 October 1998 (15.10.98)
<b>(21) International Application Number:</b> PCT/EP98/01891 <b>(22) International Filing Date:</b> 1 April 1998 (01.04.98)  <b>(30) Priority Data:</b> 97105647.8 4 April 1997 (04.04.97) EP <b>(34) Countries for which the regional or international application was filed:</b> DE et al.  <b>(71) Applicant (for all designated States except US):</b> MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. [DE/DE]; Berlin (DE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> SCHAPER, Wolfgang [DE/DE]; Am Berg 4, D-61231 Bad Nauheim (DE). ITO, Wulf, D. [DE/DE]; Wiesengrund 10, D-21335 Lüneburg (DE).  <b>(74) Agent:</b> VOSSIUS & PARTNER; Postfach 86 07 67, D-81634 München (DE).		<b>(81) Designated States:</b> CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHODS FOR THE MODULATION OF THE GROWTH OF COLLATERAL ARTERIES AND/OR OTHER ARTERIES FROM PREEXISTING ARTERIOLAR CONNECTIONS  <b>(57) Abstract</b> <p>Described is the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting tissue or cells with a monocyte chemotactic protein (MCP) or a nucleic acid molecule encoding said MCP. Furthermore, the use of a MCP or a nucleic acid molecule encoding said MCP for the preparation of pharmaceutical compositions for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections is described. Also provided are methods for the treatment of tumors comprising contacting tissue or cells with an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the attraction of monocytes. Also described is the use of an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through attraction of monocytes for the preparation of pharmaceutical compositions for the treatment of tumors.</p>		

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/19, C07K 14/52, A61K 38/19, C07K 16/24, G01N 33/68, C12N 5/18, I/21, I/19, 5/10, A61K 39/395, 39/00</b>		<b>A2</b>	(11) International Publication Number: <b>WO 99/15666</b> (43) International Publication Date: <b>1 April 1999 (01.04.99)</b>
(21) International Application Number: <b>PCT/US98/20270</b> (22) International Filing Date: <b>28 September 1998 (28.09.98)</b> (30) Priority Data: 08/939,107      26 September 1997 (26.09.97)      US 09/067,447      28 April 1998 (28.04.98)      US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US      09/067,447 (CIP) Filed on      28 April 1998 (28.04.98) US      08/939,107 (CIP) Filed on      26 September 1997 (26.09.97) US      08/660,542 (CIP) Filed on      7 June 1996 (07.06.96) US      08/558,658 (CIP) Filed on      16 November 1995 (16.11.95) US      08/479,620 (CIP) Filed on      7 June 1995 (07.06.95) (71) Applicant (for all designated States except US): <b>ICOS CORPORATION [US/US]; 22021 20th Avenue, S.E., Bothell, WA 98021 (US).</b>		(72) Inventors; and (75) Inventors/Applicants (for US only): <b>GRAY, Patrick, W. [US/US]; 1600 40th Avenue, Seattle, WA 98122 (US). CHANTRY, David, H. [GB/US]; 10350 Ashworth Avenue N., Seattle, WA 98133 (US). DEELEY, Michael, C. [US/US]; 850 Somerset Lane, Edmonds, WA 98020 (US). RAPORT, Carol, J. [US/US]; 2300 211th Street, S.E., Bothell, WA 98021 (US). GODISKA, Ronald [US/US]; 7890 Dairy Ridge Road, Verona, WI 53593 (US). (74) Agents: <b>GASS, David, A. et al.; Marshall, O'Toole, Gerstein, Murray &amp; Borun, 6300 Sears Tower, 233 S. Wacker Drive, Chicago, IL 60606-6402 (US).</b> (81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i></b>	
(54) Title: <b>MACROPHAGE DERIVED CHEMOKINE (MDC), MDC ANALOGS, MDC INHIBITOR SUBSTANCES, AND USES THEREOF</b>			
(57) Abstract <p>The present invention provides purified and isolated polynucleotide sequences encoding a novel macrophage-derived C-C chemokine designated "Macrophage Derived Chemokine" (MDC), and polypeptide fragments and analogs thereof. Also provided are materials and methods for the recombinant or synthetic production of the chemokine, fragments, and analogs; and purified and isolated chemokine protein, and polypeptide fragments and analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing. Also provided are assays for identifying modulators of MDC chemokine activity.</p>			